The Rights Issue Playbook

First published 24 Aug 2026 · Last verified 29 Aug 2026

Sabina Gurung had been a NEPSE investor for six years before she ever had to think seriously about a bank statement mid-month. She held shares in a mid-cap development bank she had bought during its post-IPO drift, added to twice on dips, and mostly ignored between quarters. Then, on a Tuesday in Falgun, her MeroShare inbox carried a notice she almost swiped past: her bank's board had recommended a 1:1 rights issue, subject to regulatory approval, to shore up capital ahead of a National Rabi Bank threshold deadline. Sabina had read Chapter 69 of this book. She understood, in principle, why banks and finance companies periodically demand fresh cash from existing shareholders, and she understood the dilution arithmetic if she declined. What she did not have, sitting at her kitchen table with the notice open on her phone and forty-two days on the clock, was a process. She did not know which button in MeroShare to press, whether her bank account needed anything done to it in advance, what would happen to her existing shares if she only had half the cash she needed, or how many days it would actually take before any new shares she bought showed up as tradable inventory in her demat account. Chapter 69 had given her the "why." This chapter exists to give Sabina — and you — the "how," in the order the calendar actually forces you to do it.

A rights issue is not a single event. It is a sequence of mechanical checkpoints, each with its own deadline, each capable of quietly costing you money if handled carelessly, and none of them forgiving of "I meant to get to it." The IPO playbook in Chapter 77 walked through a process that happens to you once, as an outsider trying to get an allocation. The rights issue playbook is different in a structural way that matters: this is your money, already committed to a company you already own, and the choice is not whether you can get in, but whether you choose to stay proportionally where you are, shrink your stake, or exit the decision to an auction process you don't control. Every step in this chapter assumes you are starting from where Sabina started — an offer letter has landed, and the clock has started.

Lesson 78.1 — Reading the Rights Offer Letter: The Notice, the Ratio, and the Deadlines That Matter

The rights process begins, for the ordinary shareholder, not with the SEBON approval or the board resolution but with a notice — delivered through MeroShare's dashboard alerts, republished in the newspapers of record as mandated disclosure, and echoed across brokerage circulars and financial portals. The notice format is standardised enough that after you've read two or three, you know exactly where to look, but the first time through it is easy to skim past the numbers that actually matter and fixate on the ones that don't.

The first number to find is the ratio. Nepali rights issues are typically expressed as an entitlement per existing share — a 1:1 issue means one new share for every share you currently hold as of the book close date; a 1:2 issue means one new share for every two you hold; some issues run at ratios like 3:10 or other non-round fractions depending on how much capital the company is raising relative to its existing paid-up base. The ratio, multiplied by your book-close holding, gives you your entitlement in kitta — and Nepali rights entitlements round down to the nearest whole share, with any residual fraction typically handled through a separate mechanism (often bundled into the auction pool for fractional and unclaimed rights, discussed in Lesson 78.4). Sabina's 1:1 entitlement against her 800-share holding meant 800 new shares available to her, no fractions to worry about — a comparatively clean case, and one of the reasons round ratios are easier to plan around than odd ones.

The second number is the book close date — the date on which the company's shareholder registry, as maintained through CDSC, is frozen to determine who is eligible for the rights entitlement. This is not the date the shares must be held through indefinitely; it is a snapshot date. If you buy shares before book close, you get the entitlement; buy them the day after, and you get nothing from this issue regardless of how long you then hold. This creates a small, well-known trading pattern around rights book closures — some investors buy just ahead of the date purely to capture entitlement, then sell down afterward — but for the ordinary long-term holder like Sabina, the book close date matters mainly as a checkpoint: it confirms the share count the rest of the math will run on.

The third and most operationally important set of numbers is the issue open date and the issue close date — the window during which the actual subscription application must be submitted. This window is where the regulatory floor set by SEBON becomes concrete: a company floating a rights issue is required to keep the subscription period open for a minimum span, conventionally around thirty-five days, with the regulator historically permitting an additional extension of roughly two weeks when initial subscription runs low — a provision that exists precisely because rights issues, unlike IPOs, often struggle to fill on time, since existing shareholders are not always liquid or paying attention. The existence of this extension window matters for your planning in one specific way: you should never plan your subscription around the assumption that an extension will happen. It is a regulator's safety valve for the issuer, not a promise to you, and treating the close date as flexible is the single most common way investors miss a rights entitlement entirely.

The fourth item worth reading closely, and the one investors skip most often, is the stated purpose of the issue and the capital deployment plan — usually a short paragraph in the offer letter or the accompanying prospectus addendum describing what the money is for. In Nepal's listed financial sector, this is frequently a regulatory capital adequacy requirement driven by Nepal Rastra Bank's minimum paid-up capital or capital-to-risk-weighted-assets mandates — a "must raise" rather than a "choose to raise" for growth. In manufacturing, hydropower, or trading companies, the stated purpose is more often project completion, debt-to-equity rebalancing ahead of a loan covenant, or working capital expansion. Chapter 69 covered why this distinction matters for the strategic decision of whether to subscribe. Operationally, it matters for a narrower reason: it tells you what kind of company you're dealing with when you go looking for financing and information in the weeks ahead, and it is often the fact set that determines whether the market's reaction to the rights announcement pushes the stock price down (dilution priced in immediately) or holds steady (market reads the capital raise as necessary and value-accretive).

Table: Anatomy of a rights offer letter — what to read, and why it matters operationally

Sabina's notice told her: 1:1 ratio, book close already fixed as of the date she was reading it (she qualified, having held the shares for over a year), a thirty-eight-day application window, an issue price at par value, and a stated purpose tied to the bank's regulatory capital requirement. Non-renounceable, as most Nepali rights issues currently are. That last detail — non-renounceable — became the single most important fact in her entire process, because it meant her only two paths forward were to subscribe, in whole or in part, or to let the entitlement lapse into the issuer's auction mechanism. There was no third option of simply selling her rights to another investor for cash, the way a renounceable structure would have allowed. Know this distinction before you do anything else, because it changes every subsequent step.

Lesson 78.2 — The MeroShare Subscription Mechanics: CRN, ASBA, and the Application Window

The mechanical act of subscribing to a rights issue in Nepal runs through the same C-ASBA infrastructure that handles IPO and FPO applications, and if you have applied for shares through MeroShare before, the screens will feel familiar. But there is one prerequisite that catches long-time buy-and-hold investors off guard precisely because they haven't touched the application flow in years: the CRN, or C-ASBA Registration Number.

The CRN links your bank account to the ASBA (Applied Specific for Blocked Amount) mechanism that Nepal's securities infrastructure uses for all primary-market applications, rights included. If you registered for a CRN years ago when you first applied for an IPO, it typically remains valid and tied to that bank account — but if you've changed your primary bank, closed the account you originally registered, or never registered one because a broker or family member handled your first application for you, you cannot get one instantly online. CRN registration requires an in-person visit to the bank branch where the account is held, and this is not something that can be rushed through in the final days of a rights window, particularly if the branch has its own processing backlog. The practical rule is straightforward: the day the rights notice appears in your MeroShare dashboard, before anything else, confirm your CRN is active against the bank account you intend to fund the subscription from. If it isn't, that errand goes to the top of your list, not the bottom.

With the CRN confirmed, the application itself follows a short, consistent sequence. Log into MeroShare, navigate to the ASBA section and then to Current Issue, where open offerings — IPOs, FPOs, and rights issues alike — are listed together with their open and close dates displayed alongside. Select the rights issue by company name, and the system will typically pre-populate your maximum entitlement based on your book-close holding, though you retain the ability to apply for fewer shares than your full entitlement — a point central to Lesson 78.4. Enter the number of kitta you intend to subscribe for, select the bank account tied to your CRN, and enter the CRN itself. The system calculates the total cash requirement — units multiplied by issue price — and this amount is not withdrawn from your account at the point of application. It is blocked, meaning it remains in your account, visible in your balance, but unavailable for other transactions until the allotment process resolves one way or the other. This is the same ASBA principle that governs IPO applications, and it is worth restating because it removes one common anxiety: applying for a rights subscription does not mean sending money into a void and hoping shares arrive. The bank holds a claim against the funds; it does not take custody of them.

After entering the application details, you confirm through an OTP sent to your registered mobile number, and the system issues an application reference. As with IPO applications, save this reference — it is your lookup key if you need to check status or, in the rare event of a system dispute, prove that a submission was made before the deadline. The application then sits in a pending state until the issue closes, allotment is processed, and results are published under My Application in MeroShare, at which point subscribed shares move toward crediting (Lesson 78.5) and any unblocked balance is released.

Two operational cautions belong in this lesson because they are exactly the kind of detail a book about strategy tends to skip and a real investor tends to discover the hard way. First, submitting your application on the final day of the window is legally permitted but practically unwise — MeroShare's servers, like most retail financial platforms in Nepal, experience load spikes in the closing hours of high-interest issues, and a failed submission at 4:55 PM with the window closing at 5:00 PM leaves you no recourse. Second, once submitted, a rights application can typically be edited or withdrawn only within a limited window before the issue closes, through the same Application Report screen used to track status — if you discover a data entry error, correcting it promptly matters more than it does with an IPO application, since you cannot simply reapply if you have already exhausted your entitlement in a wrong-value submission.

Lesson 78.3 — Financing the Cash Call: Bridging, Timing, and the Cost of Capital You Didn't Plan For

A rights issue is, from the shareholder's side of the ledger, an unscheduled cash call arriving on a company's timetable rather than yours. This is the operational fact that separates rights issue planning from ordinary portfolio management: you did not choose the date, you did not choose the amount, and if your portfolio is meaningfully invested — which, if you're a serious NEPSE participant, it likely is — the full subscription amount for a large holding is not sitting in a current account waiting to be deployed. Sabina's 800-share entitlement at par value meant a cash requirement in the tens of thousands of rupees, a sum she did not have sitting idle, because her working capital habit was to stay close to fully invested.

The financing question therefore resolves into three sub-questions, and answering them in the right order prevents a rushed, expensive decision in the final week of the window.

The first sub-question is whether you have the cash without touching your portfolio at all — from salary timing, a maturing fixed deposit, a bonus, or simple accumulated savings. This is the cheapest path by a wide margin, because it carries no transaction cost, no capital gains tax event, and no market-timing risk. If the answer is yes, the rest of this lesson is not about you, and you should simply schedule the transfer to your ASBA-linked account with a few days of buffer before the close date.

The second sub-question, and the one that applies to most actively invested shareholders, is whether raising the cash requires selling something else in your portfolio — and if so, what, and when. This is where "bridging from other holdings" stops being an abstract phrase and becomes a concrete, dated plan. The mechanical reality of NEPSE settlement (T+2 for equity trades, as covered in the market plumbing chapters of this book) means that if you plan to sell Holding A to fund your rights subscription in Holding B, you need the sale proceeds to actually settle and reach your bank account before your ASBA application deadline — not merely to have placed the sell order. Selling three days before the rights close date, expecting same-day liquidity, is a common and entirely avoidable mistake. The safe rule of thumb is to initiate any funding sale at least a full week ahead of the intended subscription date, giving settlement, bank transfer processing, and CRN-linked account crediting enough slack to clear comfortably.

The choice of what to sell matters as much as the timing. Selling a core, high-conviction long-term holding to fund a rights subscription in a company you hold with lower conviction inverts your own portfolio logic — you would be shrinking your best position to grow a weaker one, purely because the weaker one happens to be the one demanding cash on a fixed schedule. The more disciplined approach, consistent with the position-sizing and rebalancing frameworks built earlier in this book, is to fund the rights call from your lowest-conviction liquid holdings first, treating the rights subscription itself as simply another capital allocation decision competing for the same pool of investable rupees — not a special, protected category that automatically deserves funding ahead of everything else in your portfolio.

The third sub-question, often skipped, is whether the financing source itself carries a hidden cost that changes the real economics of subscribing. Selling a holding that has appreciated triggers a capital gains tax liability under Nepal's capital gains framework for listed securities — a cost that reduces the net cash actually available for the subscription and should be netted against the funding calculation, not treated as separate. Borrowing against securities through a margin facility, where available, carries an explicit interest cost that needs to be compared against the rights issue's own economics — subscribing to a rights issue using margin-funded cash only makes sense if your conviction in the post-rights company, including the theoretical ex-rights price math, clears the hurdle rate of the borrowing cost plus a margin of safety. Treating "the money is available" and "the money is free" as the same statement is the most quietly expensive mistake in rights issue financing.

Sabina's own resolution illustrates the ordering discipline this lesson argues for. She did not have the full subscription amount in cash. Rather than reflexively selling a portion of her core hydropower holding — the position she had the highest long-term conviction in — she reviewed her portfolio for the lowest-conviction liquid line item, a small trading-sector position she had been meaning to trim anyway, and sold roughly that amount, timing the sale twelve days before her rights application deadline to leave comfortable settlement and transfer buffer. The proceeds cleared into her bank account nine days ahead of the deadline, giving her three days of margin even after accounting for the CRN-linked ASBA transfer. This is not a dramatic story, and that is precisely the point: rights issue financing done correctly should be unremarkable, a matter of scheduling rather than scrambling.

Lesson 78.4 — Partial Subscription, Renunciation, and the Mechanics of Letting It Lapse

Full subscription to your entire entitlement is the default assumption most investors carry into a rights issue, but it is not the only rational choice, and MeroShare's application form explicitly permits subscribing for fewer shares than your maximum entitlement. Understanding the mechanics of each fallback path — partial subscription, renunciation where available, and outright lapse — turns the rights decision from a binary in-or-out choice into a genuine spectrum of choices matched to your actual financial position.

Partial subscription is the most commonly used middle path for shareholders who believe in the company but cannot or do not want to fund the full entitlement. Mechanically, this is simple: on the application form, you enter a kitta count below your maximum entitlement, and the ASBA block is calculated against that lower number. The consequence is proportional and mechanical, not punitive — you receive new shares equal to whatever fraction of your entitlement you funded, and your ownership percentage in the company dilutes by the unfunded portion, exactly as the Chapter 69 dilution math describes. There is no penalty tier for partial subscription and no requirement to explain your reasoning; the system treats a partial application exactly like a full one, just smaller.

Renunciation, where the issue structure permits it, is a different mechanism entirely — a genuine transfer of the entitlement itself to another party, who then subscribes and receives the shares in their own name, typically in exchange for a payment negotiated between the two parties for the value of the right. This is the closest thing to "selling your rights" in the Nepali market, and it requires action within the issue's open window, following whatever transfer procedure the specific issue's letter specifies — it is not a MeroShare self-service toggle in the way subscribing or not subscribing is. Because the overwhelming majority of rights issues currently seen in NEPSE's financial sector are structured as non-renounceable, this path is the exception rather than the rule, and confirming which structure you're facing (Lesson 78.1) determines whether it's even on the table for you.

Letting the entitlement lapse — applying for nothing, deliberately or by inaction — is the third path, and it is the one investors understand least clearly, often assuming incorrectly that an unclaimed entitlement simply evaporates with no further consequence beyond dilution. What actually happens is more specific: shares corresponding to entitlements that go unsubscribed by the close date, along with fractional remainders from the ratio rounding described in Lesson 78.1, are pooled by the issuer and typically placed into an auction process, sold to interested subscribers — often existing shareholders who applied for more than their base entitlement, where the issue structure allows over-subscription requests, or to the general investing public through a separate mechanism specified in the issue documents. The proceeds of that auction, after adjusting for the original issue price and any auction premium, are frequently required to be routed back toward the company or held per SEBON's directions rather than returned to the shareholder who let the entitlement lapse — meaning the lapsed shareholder captures none of whatever value the auction realises. This is the single fact that most sharply distinguishes "choosing not to subscribe" from "letting it lapse": a deliberate decision not to subscribe is a dilution choice with a known, bounded cost; a lapse driven by inattention forfeits even the residual value that an active choice not to subscribe would have preserved via renunciation, if that path existed.

Table: The four mechanical paths through a rights issue, and what each one actually does to your position

Sabina's case resolved as a full subscription, once her financing plan (Lesson 78.3) closed the cash gap — but the discipline of the decision worksheet in Lesson 78.6 is exactly what would have told her, had her financing not come together in time, that a partial subscription funded entirely from cash on hand was a strictly better outcome than either scrambling to sell a core holding under time pressure or letting the full entitlement lapse by default. The mechanical options exist precisely so that the financing constraint does not have to force an all-or-nothing outcome.

Lesson 78.5 — After You Click Submit: Allotment, Crediting, and the Listing Lag

Submitting a rights subscription application is not the end of the process; it is the midpoint. The period between the issue close date and the point at which subscribed shares actually become tradable inventory in your demat account is where a second, less visible kind of patience is required — and where investors who expect IPO-like speed are often surprised by how much longer a rights issue's back-office resolution can take.

Once the application window closes, the issuer and its share registrar reconcile the applications received, resolve any over-subscription of the auction pool for lapsed and fractional entitlements described in Lesson 78.4, and finalise the allotment. This finalised allotment then requires processing through CDSC to actually credit the new shares into each subscriber's demat account, and, separately, an approval from NEPSE to list the new shares for trading — a company cannot simply issue shares and have them tradable the instant CDSC crediting occurs; the newly issued shares must clear NEPSE's listing formalities, which is itself a distinct regulatory step following allotment, not a formality that happens automatically or instantly. In practice, the gap between allotment finalisation and the shares actually appearing as tradable in your MeroShare portfolio has commonly run to several weeks in the Nepali market — a period during which your subscription cash has already been debited (converted from an ASBA block to an actual payment) but the corresponding shares are not yet visible, let alone sellable.

A useful, widely cited rule of thumb from experienced NEPSE participants is that once a company's newly issued shares receive NEPSE's trading approval, crediting into demat accounts and readiness for trading typically follows within about a week — but that week only starts once listing approval is granted, and getting from allotment finalisation to listing approval is the longer, less predictable leg of the journey, often stretching to a month or more depending on how quickly the registrar and CDSC process the batch and how promptly NEPSE grants listing. The practical implication for your own planning is straightforward: do not assume you will be able to trade your new rights shares the week after the issue closes, and do not treat the interval as evidence something has gone wrong. Track status through MeroShare's My Portfolio and My Application sections, and treat the appearance of the new shares as tradable inventory — not merely as an allotment confirmation — as the actual finish line.

Table: The rights issue timeline, notice to tradable shares (illustrative sequencing)

For Sabina, this meant a genuine gap of roughly six weeks between her application submission and the morning she logged into MeroShare to find 800 new shares sitting as tradable inventory in her portfolio, at which point the cash that had been blocked against her ASBA account for those six weeks was long since converted into an actual subscription payment. Nothing about that gap indicated a problem; it is simply the mechanical reality of how allotment, listing, and crediting sequence through CDSC and NEPSE, and planning your own liquidity and expectations around that reality — rather than around the faster cadence some IPO processes have trained investors to expect — is part of executing a rights subscription competently rather than anxiously.

Lesson 78.6 — The Four-Question Decision Worksheet: A Step-by-Step Fillable Framework

Chapter 69 established the four questions that should govern any rights issue decision at the conceptual level: what the capital is actually for, whether the post-rights economics still make sense, whether you can afford the cash call without distorting your broader portfolio, and what your fallback path looks like if you choose not to fund the full entitlement. This lesson turns those four questions into an actual worksheet — a sequence you fill in, in order, against the real notice sitting in front of you, producing a specific action rather than a general disposition.

Question One: What is the capital actually for, and do you believe the stated use case? Write down, in one sentence, the stated purpose from the offer letter — regulatory capital mandate, project completion, debt rebalancing, working capital, or acquisition financing. Then write down whether this is a "must raise," where the company has essentially no choice (an NRB capital directive is the clearest Nepali example), or a "choose to raise," where management is electing to fund growth through shareholder cash rather than debt or retained earnings. A must-raise scenario changes the character of the decision: the question is no longer "is this a good use of capital" but "do I still want to own this company at all, given that this cash call is now unavoidable and recurring in nature until the capital threshold is durably met." A choose-to-raise scenario keeps the traditional capital allocation question front and centre — would you, as a rational allocator, choose to put new money into this specific project at this specific valuation if you were looking at it fresh today.

Question Two: What does the post-rights arithmetic actually look like? Calculate the theoretical ex-rights price — the blended price the stock should trade at immediately after the rights shares are issued, given the dilution. The formula is straightforward: multiply the current market price by the number of shares you hold, add the issue price multiplied by the new shares you're entitled to, and divide the sum by your total post-rights share count. Compare that theoretical ex-rights price against the company's underlying fundamentals — book value, earnings trajectory, the reason you owned the stock in the first place. If the theoretical ex-rights price still clears your original investment thesis with a reasonable margin of safety, subscribing preserves a position you'd still want to hold at that price. If the theoretical ex-rights price sits above what you'd pay for the stock fresh today, that is a signal worth taking seriously before writing the check, regardless of how attached you are to your existing position.

Question Three: Can you fund this without distorting your broader portfolio? Run the financing sub-questions from Lesson 78.3 in order: cash on hand first, then identification of your lowest-conviction liquid holding as a funding source if a sale is required, then an honest accounting of the tax and opportunity cost of that sale, then — only if genuinely necessary — the cost of any margin facility, compared explicitly against your Question Two arithmetic. Write down the specific rupee amount you can fund without selling anything, and the specific rupee amount you could additionally raise through a sale you've already identified and are comfortable with. These two numbers, added together, are your real ceiling — not your full entitlement value, unless the two happen to match.

Question Four: What is your fallback path, matched against your Question Three ceiling? If your funding ceiling covers your full entitlement, subscribe fully and move to the MeroShare mechanics of Lesson 78.2, scheduled with the buffer discipline described there. If your ceiling covers only part of your entitlement, decide deliberately — not by default — whether a partial subscription at that ceiling is preferable to stretching for the full amount through a financing source you rated poorly in Question Three; the worksheet's discipline is that a deliberate partial subscription, chosen in week two, always beats a rushed full subscription financed by whatever is fastest to liquidate in week five. If your ceiling is effectively zero and the issue is renounceable, investigate the renunciation procedure specified in the offer letter before the window closes. If your ceiling is zero and the issue is non-renounceable, accept the lapse consequence as a known, bounded dilution cost rather than letting the deadline pass unexamined — the difference between an active decision to let an entitlement lapse and a passive one is not visible in the mechanical outcome, but it is the entire difference between disciplined investing and drift.

Table: The worksheet, filled in for a hypothetical live rights notice